Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06650566
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Study of LM-299 in Subjects Advanced Malignant Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase III Open-label Dose Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of LM-299 Injection Alone or in Combination With Other Antitumor Agents in Subjects With Advanced Solid Tumours
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and tolerability obtain Maximum Tolerated Dose MTD or optimal biological dose OBD and the recommended phase 2 dose RP2D for LM-299 in subjects with advanced solid tumours
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None